BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1100 related articles for article (PubMed ID: 28990165)

  • 1. Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Reed ML; Kurth T; Fanning KM; Buse DC
    Headache; 2017 Nov; 57(10):1507-1521. PubMed ID: 28990165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Reed ML; Fanning KM; Kurth T; Lipton RB
    Headache; 2017 Jan; 57(1):31-44. PubMed ID: 27861837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
    Lipton RB; Manack Adams A; Buse DC; Fanning KM; Reed ML
    Headache; 2016 Sep; 56(8):1280-9. PubMed ID: 27349336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
    Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptan use as a function of cardiovascular risk. A population-based study.
    Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
    Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
    Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study.
    Martin VT; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    Headache; 2016 Jan; 56(1):118-31. PubMed ID: 26581563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
    Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D; Manack AN; Reed ML; Buse DC; Varon SF; Lipton RB
    Value Health; 2013; 16(1):31-8. PubMed ID: 23337213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established cardiovascular disease and CVD risk factors in a primary care population of middle-aged Irish men and women.
    Creagh D; Neilson S; Collins A; Colwell N; Hinchion R; Drew C; O'Halloran D; Perry IJ
    Ir Med J; 2002; 95(10):298-301. PubMed ID: 12542011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
    Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
    Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Loder EW; Gorman JA; Stewart WF; Reed ML; Fanning KM; Serrano D; Lipton RB
    Headache; 2013 Sep; 53(8):1278-99. PubMed ID: 23808666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Serrano D; Pavlovic JM; Manack AN; Reed ML; Turkel CC; Buse DC
    Headache; 2014 May; 54(5):830-49. PubMed ID: 24527745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.